Valuation: Agios Pharmaceuticals, Inc.

Market Cap 2B 1.73B 1.63B 1.48B 2.78B 192B 2.83B 19.05B 7.45B 95.94B 7.52B 7.36B 319B P/E 2026 *
-5.91x
P/E 2027 * -8.69x
Enterprise Value 1.75B 1.51B 1.42B 1.29B 2.42B 167B 2.46B 16.6B 6.49B 83.6B 6.56B 6.41B 278B EV / Sales 2026 *
9.57x
EV / Sales 2027 * 5.49x
Free-Float
77.8%
Yield 2026 *
-
Yield 2027 * -
1 day+0.27%
1 week+4.00%
Current month+11.79%
1 month-13.33%
3 months+19.13%
6 months+20.03%
Current year+23.29%
1 week 32.22
Extreme 32.22
34.65
1 month 29.15
Extreme 29.15
40.5
Current year 24.29
Extreme 24.29
44.09
1 year 22.24
Extreme 22.24
46
3 years 19.8
Extreme 19.795
62.58
5 years 16.75
Extreme 16.75
62.58
10 years 16.75
Extreme 16.75
99.82
Manager TitleAgeSince
Chief Executive Officer 57 08/08/2022
Director of Finance/CFO 51 26/09/2022
Chief Tech/Sci/R&D Officer 47 01/09/2021
Director TitleAgeSince
Director/Board Member 66 09/12/2014
Director/Board Member 73 23/06/2015
Director/Board Member 73 27/05/2017
Date Insider Type Main position Quantity % Market Cap.
8/4/26 A Sell

Chief Technology Officer

-30,000 0.0504%
7/8/26 A Free

Director

2,894 0.0049%
7/1/26 A Fiscal year

Chief Technology Officer

20,757 0.0349%
Change 5-day change 1-year change 3-year change Capi.($)
+0.27%+4.00%-9.32%+25.69% 2B
-1.90%+2.85%+62.82%+104.39% 70.07B
+7.83%+2.69%+37.36%+72.49% 52.87B
-2.05%-5.61%-3.18%+449.22% 27.02B
+2.13%-0.04%+48.71%+11.76% 23.61B
+1.05%-0.62%-18.00%-13.77% 23.38B
+3.81%+20.97%+266.37%+477.93% 19.43B
+2.12%+3.92%+37.31%-16.63% 18.75B
-0.10%-1.61%+16.38%+564.11% 15.85B
+1.24%-5.23%+33.75%+140.34% 12.7B
Average +1.44%-0.40%+47.22%+181.55% 26.57B
Weighted average by Cap. +1.62%-1.36%+51.06%+161.82%

Financials

2026 *2027 *
Net sales 182M 158M 148M 135M 253M 17.45B 257M 1.74B 679M 8.74B 685M 670M 29.04B 340M 294M 276M 251M 472M 32.5B 479M 3.23B 1.26B 16.27B 1.28B 1.25B 54.08B
Net income -338M -292M -274M -250M -469M -32.32B -477M -3.21B -1.26B -16.19B -1.27B -1.24B -53.79B -240M -207M -195M -177M -333M -22.96B -339M -2.28B -893M -11.5B -902M -882M -38.21B
Net Debt -258M -223M -209M -190M -358M -24.64B -363M -2.45B -958M -12.34B -967M -946M -41B -137M -119M -112M -101M -191M -13.14B -194M -1.31B -511M -6.58B -516M -505M -21.86B
Logo Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Employees
540
Date Price Change Volume
14/08/26 $33.56 +0.27% 1,124,478
13/08/26 $33.47 -2.16% 939,123
12/08/26 $34.21 +4.65% 1,223,093
11/08/26 $32.69 +0.31% 938,748
10/08/26 $32.59 +0.99% 1,071,534
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
33.56USD
Average target price
45.75USD
Spread / Average Target
+36.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGIO Stock